Koops S, Allott K, de Haan L, Chen E, Hui C, Killackey E, Long M, Moncrieff J, Sommer I, Stürup A, Wunderink L, Begemann M, van der A J, Bakker P, Beer F, Begemann M, van Beveren N, Boonstra T, Brand B, Djordjevic M, Franke S, Gangadin S, Guloksuz S, Haan L, van ‘t Hag G, Hamers I, van der Heijden-Hobus I, Hoornaar R, Huizer K, Kikkert M, Koops S, Lokkerbol J, Marcelis M, Oomen P, van Os J, Rosema B, Sommer I, Smit F, Veling W, Voppel A, Albert N, Karlsen M, Nordentoft M, Speyer H, Stürup A, Allott K, Killackey E, O’Donoghue B, Stainton A, Cooper R, Conneely M, Grünwald L, Haynes N, Horowitz M, Mason J, Long M, Moncrieff J, Priebe S, Stansfeld J, Vasiliki G, Chen E, Hui C, Wunderink L, Liu C, Berna F, Foucher J. Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium. Schizophrenia Bulletin 2023, 50: 5-8. PMID: 37625022, PMCID: PMC10754158, DOI: 10.1093/schbul/sbad112.Peer-Reviewed Original Research